Exopharm Limited announced that it is building multiple streams of revenue from licensing and partnerships. Enabling leading blood service organizations to manufacture new extracellular vesicle (EV) medicines from their blood components using Exopharm's LEAP technology is part of that strategy. Out of this commercial activity comes a non-binding Heads of Agreement with the Finnish Red Cross Blood Service (FRCBS). The HOA sets out the basis for FRCBS to conduct due diligence, and for both parties to undertake further discussions in relation to entering into a definitive agreement for FRCBS to license Exopharm's LEAP technology on commercial terms and to produce and sell EVs isolated from blood components using LEAP.